Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immunocore Holdings (IMCR) Operating Expenses: 2021-2025

Historic Operating Expenses for Immunocore Holdings (IMCR) over the last 3 years, with Sep 2025 value amounting to $110.4 million.

  • Immunocore Holdings' Operating Expenses rose 24.97% to $110.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $422.0 million, marking a year-over-year increase of 16.65%. This contributed to the annual value of $377.9 million for FY2024, which is 22.69% up from last year.
  • As of Q3 2025, Immunocore Holdings' Operating Expenses stood at $110.4 million, which was down 1.30% from $111.8 million recorded in Q2 2025.
  • Over the past 5 years, Immunocore Holdings' Operating Expenses peaked at $111.8 million during Q2 2025, and registered a low of -$60.0 million during Q4 2021.
  • For the 3-year period, Immunocore Holdings' Operating Expenses averaged around $91.3 million, with its median value being $89.7 million (2024).
  • Per our database at Business Quant, Immunocore Holdings' Operating Expenses surged by 39.93% in 2024 and then declined by 0.08% in 2025.
  • Immunocore Holdings' Operating Expenses (Quarterly) stood at -$60.0 million in 2021, then reached $87.0 million in 2023, then grew by 18.57% to $103.2 million in 2024, then climbed by 24.97% to $110.4 million in 2025.
  • Its last three reported values are $110.4 million in Q3 2025, $111.8 million for Q2 2025, and $96.7 million during Q1 2025.